A Phase 1 interventional study of Cromolyn Sodium in Locally Advanced Non-Small Cell Lung Cancer and Lung Adenocarcinoma, sponsored by Carcinex Inc. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Carcinex Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Adenocarcinoma of Lung with a site in United States — 16 open to participants now, 31 under way, 2 of them phase 3. Adenocarcinoma of Lung · United States.
Among the 206 studies in Adenocarcinoma of Lung with a site in United States, this one is the 156th largest by planned enrollment of the 179 interventional ones that give a count, is one of 3 that started in 2026, is one of 46 in phase 1, reaches primary completion later than 13 of the 30 other live ones, and was the 205th registered.
418 studies on the registry are indexed under Adenocarcinoma of Lung; 79 are open to participants now.
Browse Adenocarcinoma of Lung studies →16 of the 206 studies in Adenocarcinoma of Lung with a site in United States are open now. Recruiting first, the newest first:
Duboce Biopharmaceuticals, Inc. · Sites in United States
Ages 18+
Palo Alto Veterans Institute for Research · Sites in United States
Ages 18+
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 22+
Anusha Kalbasi · Sites in United States
Ages 18–75
University of Pennsylvania · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 58 Adenocarcinoma of Lung studies recruiting now, 36 (62%) set no upper age limit and 10 (17%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 69 · Phase 2 114 · Phase 3 24
First in 1994; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 60 across 293 interventional studies indexed under Adenocarcinoma of Lung.
Median enrollment 50 across the 179 interventional studies, 244 across the 15 observational. Of the 162 that completed or were terminated, 72 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 206 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Carcinex Inc as lead sponsor.
Carcinex Inc has 1 study filed under Adenocarcinoma of Lung — fewer than ten, so there is no comparison to draw.
11 of the studies in Adenocarcinoma of Lung with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03391869Phase 3M.D. Anderson Cancer CenterNivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | 2027-03-31 |
| NCT05456256Lantern Pharma Inc.A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | 2026-12 |
| NCT04625647SWOG Cancer Research NetworkTesting the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | 2026-12-31 |
| NCT03199651Ohio State University Comprehensive Cancer CenterBeating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer | 2026-12-31 |
| NCT01345851Jonsson Comprehensive Cancer CenterImage-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | 2027-01-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 206 studies in Adenocarcinoma of Lung with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Brief Summary
This prospective, open-label pilot study is designed to evaluate the safety, tolerability, feasibility, and preliminary clinical activity of inhaled cromolyn sodium administered by dry powder inhalation in participants with locally advanced lung cancer.
Cromolyn sodium is an FDA-approved mast cell stabilizer with an established safety profile in respiratory disease. Increasing evidence suggests that inflammatory signaling, mast cell activation, and stromal remodeling contribute to tumor progression, immune dysregulation, and resistance to therapy within the lung tumor microenvironment. Modulation of these pathways may represent a novel therapeutic strategy in lung cancer.
Approximately 5 to 10 participants with locally advanced lung cancer will receive inhaled cromolyn sodium according to the study protocol. Participants will undergo clinical assessments, safety monitoring, laboratory evaluations, and radiographic imaging in accordance with protocol-defined procedures and standard oncologic care.
The primary objective of this pilot study is to evaluate the safety, tolerability, and feasibility of inhaled Cromolyn sodium administration in this patient population. Secondary objectives include exploratory assessment of radiographic response, clinical outcomes, biomarker trends, and potential signals of biological activity. Data generated from this study are intended to support the development of future clinical investigations evaluating the role of mast cell stabilization and tumor microenvironment modulation in lung cancer.
Scientific Background and Rationale
Lung cancer remains a leading cause of cancer-related mortality worldwide despite substantial advances in molecularly targeted therapies, immunotherapy, radiation therapy, and multimodality treatment approaches. Increasing evidence indicates that, in addition to intrinsic tumor biology, the tumor microenvironment plays a critical role in disease progression, immune evasion, therapeutic resistance, and metastatic dissemination. Consequently, there is growing interest in therapeutic strategies designed to modulate tumor-associated inflammatory and stromal processes that contribute to cancer progression.
Mast cells are resident immune cells that participate in both innate and adaptive immune responses and are increasingly recognized as important components of the tumor microenvironment. In lung cancer, mast cell infiltration has been observed within both primary tumor tissue and surrounding stromal compartments. Experimental and translational studies have suggested that mast cells may contribute to tumor-associated inflammation through the release of cytokines, chemokines, growth factors, angiogenic mediators, and proteolytic enzymes capable of influencing immune regulation, angiogenesis, extracellular matrix remodeling, and cellular proliferation.
Cromolyn sodium is an FDA-approved mast cell stabilizing agent with a long-established clinical safety profile following inhalational administration for allergic respiratory disorders. The drug inhibits mast cell degranulation and reduces the release of multiple inflammatory mediators involved in downstream immune and inflammatory signaling pathways. In addition to its effects on mast cells, preclinical investigations have suggested broader effects on inflammatory processes involving macrophages, eosinophils, neutrophils, and other immune-regulatory cell populations implicated in tumor-associated inflammation.
Preclinical studies evaluating mast cell inhibition and modulation of inflammatory signaling pathways have generated interest in the potential role of tumor microenvironment-directed therapeutic strategies in solid tumors. Although the clinical significance of these observations remains uncertain, available experimental data provide a biologically plausible rationale for exploratory clinical investigation of cromolyn sodium in lung cancer.
The pulmonary route of administration offers additional scientific rationale for evaluation in this setting. Inhaled drug delivery permits direct deposition of therapeutic agents within the respiratory tract and may facilitate local exposure within pulmonary tissues while limiting systemic drug exposure. Administration by dry powder inhaler may provide efficient pulmonary delivery and represents a practical, non-invasive method of drug administration that can be implemented in both clinical and home-based settings.
Cromolyn sodium has demonstrated a favorable safety profile during decades of clinical use. Systemic absorption following inhalation is limited, systemic toxicity is uncommon, and the drug is not associated with many of the adverse effects characteristic of conventional cytotoxic anticancer therapies. Nevertheless, the use of inhaled cromolyn sodium for the treatment of lung cancer remains investigational and has not been established as safe or effective for this indication.
Given the established clinical safety profile of inhaled cromolyn sodium, its biologic activity as a mast cell stabilizer, the emerging understanding of inflammatory and stromal mechanisms in lung cancer progression, and the potential advantages of localized pulmonary drug delivery, a pilot clinical investigation is warranted to evaluate the safety, feasibility, tolerability, and preliminary clinical activity of inhaled cromolyn sodium in participants with locally advanced lung cancer.
Safety Considerations
Participants enrolled in this study will undergo protocol-defined safety monitoring throughout the treatment and follow-up periods. Safety assessments will include evaluation of treatment-emergent adverse events, respiratory symptoms, hypersensitivity reactions, clinically significant laboratory abnormalities, and other changes in clinical status. Given the investigational nature of this treatment approach, ongoing safety surveillance will be conducted throughout study participation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with local advanced stage 3 lung cancer or lung adenocarcinoma will be eligible for the study only if they meet the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with locally advanced lung cancer will receive cromolyn sodium administered by oral inhalation using a dry powder inhaler according to the study protocol.
Drug: Cromolyn Sodium
Cromolyn sodium administered by oral inhalation using a dry powder inhaler. Treatment will be administered according to the protocol-defined dosing schedule throughout the study period.
Also known as: Sodium Cromoglycate
Safety and Tolerability of Inhaled Cromolyn Sodium
Incidence, severity, and frequency of treatment-emergent adverse events and serious adverse events during study participation.
Time frame: Up to 12 months
Radiographic Tumor Response
Exploratory assessment of changes in tumor burden based on clinically obtained imaging studies.
Time frame: Baseline through 12 months
Feasibility of Treatment Administration
Assessment of participant completion of protocol-defined treatment and study procedures.
Time frame: Up to 12 months
Plan to share: Undecided
Start is estimated for Aug 2026; primary completion for Jun 2027, 10 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cromolyn